Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    treprostinil | RIN-PH-403 | United States, Florida
Show Display Options
Rank Status Study
1 Completed Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: inhaled prostacyclin;   Drug: prostacyclin;   Drug: subcutaneous and intravenous prostacyclin;   Drug: oral ERA;   Drug: oral PDE5 inhibitors

Indicates status has not been verified in more than two years